default author photo

Kanta Subbarao

University of Melbourne

Carlton

Parkville, 3010

Australia

SCHOLARLY PAPERS

2

DOWNLOADS

250

TOTAL CITATIONS

0

Scholarly Papers (2)

1.

Interim Results from a Phase I Trial of Novel SARS-CoV-2 Beta Variant Receptor-Binding Domain Recombinant Protein and mRNA Vaccines as a 4 th Dose Booster

Number of pages: 43 Posted: 29 Jun 2023
University of Melbourne - Peter Doherty Institute for Infection and Immunity, University of Melbourne, University of Melbourne, University of Melbourne - Departments of Medicine and Infectious Diseases at the Doherty Institute, University of Melbourne - Department of Microbiology and Immunology, University of Melbourne - Peter Doherty Institute for Infection and Immunity, University of Melbourne - Peter Doherty Institute for Infection and Immunity, University of Melbourne, University of Melbourne, University of Melbourne, Flinders University, University of Melbourne, University of Melbourne, University of Melbourne, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Peter Doherty Institute for Infection and Immunity, University of Melbourne, University of Melbourne - Department of Microbiology and Immunology, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne, University of Melbourne, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne, University of Melbourne - Royal Melbourne Hospital, University of Melbourne - Centre for Epidemiology and Biostatistics, University of Melbourne, Monash University - Monash Institute of Pharmaceutical Sciences, Monash University - Monash Institute of Pharmaceutical Sciences, Monash University - Monash Institute of Pharmaceutical Sciences, SingHealth Duke-NUS Global Health Institute, University of Melbourne - Department of Microbiology and Immunology (DMI), Flinders University, Duke-NUS Medical School - Programme in Emerging Infectious Diseases, Monash University - Monash Institute of Pharmaceutical Sciences, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Centre for Epidemiology and Biostatistics, Monash University - Monash Institute of Pharmaceutical Sciences and University of Melbourne - Department of Microbiology and Immunology (DMI)
Downloads 130

Abstract:

Loading...

SARS-CoV-2, vaccine, receptor binding domain, recombinant protein, mRNA, beta variant, phase I trial.

2.

Preclinical Evaluation of a Cross-Protective ß-SARS-CoV-2 Virus-Like Particle Vaccine Adjuvanted with MF59

Number of pages: 52 Posted: 26 Mar 2024
University of Melbourne - Department of Microbiology and Immunology (DMI), University of New South Wales (UNSW), University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), La Trobe University - Department of Biochemistry & Chemistry, The Walter and Eliza Hall Institute of Medical Research, The Walter and Eliza Hall Institute of Medical Research, University of Melbourne, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Royal Melbourne Hospital, University of Melbourne - Royal Melbourne Hospital, SingHealth Duke-NUS Global Health Institute, Duke-NUS Medical School - Programme in Emerging Infectious Diseases, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne, University of Melbourne - Royal Melbourne Hospital, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne, The Walter and Eliza Hall Institute of Medical Research, University of Melbourne, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI) and University of Melbourne - Department of Microbiology and Immunology (DMI)
Downloads 120

Abstract:

Loading...

SARS-CoV-2, COVID-19 variants, vaccine, virus-like particles, VLP, receptor-binding domain, RBD